Recently, Omai Gold Mines announced additional positive drill results from its Omai gold project, including high-grade intercepts at the SP exploration target, noted Atrium Research analysts Ben Pirie and Nicholas Cortellucci.
This is expected to come on the heels of the Canadian silver producer resuming operations after a nearly three-month halt during Q3/23, noted a Red Cloud Securities report.
Defense Metals Corp. recently filed a NI 43-101 MRE technical report for its Wicheeda Rare Earth Element Project, noted Noble Capital analyst Mark Reichman.
Recently, Arcus Biosciences Inc. announced a partnership with Exelixis Inc., which may be the key to validating the company, noted WedBush analysts in a December 4 report.
DroneShield Ltd. is expected to deliver over AU$69 million in revenue for 2023, approximately 4x last year's result, noted Bell Potter analyst Daniel Laing.
While recent third-quarter financial results were not aligned with expectations, Volatus Aerospace has positives in the strong growth of recurring services, noted Echelon analyst Rob Goff.
Recently, BriaCell Therapeutics Corp. announced a new exceptional responder in its Phase 2 study evaluating the company's off-the-shelf personalized immunotherapy, noted H.C. Wainwright analyst Emily Bodnar.
This young firm with 162% return potential uses a proprietary, carbon-negative process to transform biomass waste into industrial products, noted a Paradigm Capital report.
Recently, SpringWorks Therapeutics Inc. announced FDA approval of OGSIVEO (nirogacestat) for treating progressing desmoid tumors (DT) in adult patients based on Phase 3 DeFi trial results, noted H.C. Wainwright & Co. analysts Robert Burns and Dr. Raghuram Selvaraju.
Recently, Seabridge Gold Inc. announced Tudor Gold's request to cancel its license of occupation and permit was not victorious, reported Red Cloud analysts Taylor Combaluzier and David A. Talbot in a November 21 research note.
In a recent corporate update, Purple Biotech Ltd. reported positive interim Phase 1/2 data for NT219 and accelerated enrollment for CM24, noted H.C. Wainwright analyst Emily Bodnar.
Oren Livnat of H.C. Wainwright & Co. sees over 240% upside potential for Verrica Pharmaceuticals based on the early commercial success of its recently launched skin disease treatment.
Better-than-expected flows and a discovery from one well plus greater volumes out of another should positively impact future production totals, noted an Auctus Advisors report.
Stephane Foucaud at Auctus Advisors sees over 90% upside for Panoro Energy based on increased reserves, new exploration potential, and improving fundamentals.
Roth MKM has a US$30 price target on this biotech company based on progress across its regenerative medicine pipeline, including upcoming Phase 1/2 data.
This event follows a month-long delay in drilling due to a mechanical issue and creating a new operational plan, noted a Research Capital Corp. report.
Wedbush sees over 300% upside for Werewolf stock based on early clinical success for its PREDATOR platform and pipeline, according to a WedBush research note.
eResearch sees over 100% upside for DATA Communications stock based on growth and synergies from the Moore Canada deal, noted eResearch analyst Chris Thompson.
This payment follows the Mexican silver mining operation transitioning to sole use of its own new processing plant and reaching nameplate production capacity, noted a BMO Capital Markets report.